CCR2 and breast cancer: While IgD+CD24+%B cell (p-value=0.0282; B cell panel), CD28+ CD45RA+ CD8dim AC (p-value=0.0284; Treg panel), CD28+ CD45RA+ CD8br %T cell (p-value=0.0013; Treg panel), CD3 on CD28+ DN (CD4-CD8-) (p-value=0.0322; Treg panel), Activated & secreting Treg %CD4+ (p-value=0.0456; Treg panel), CD33- HLA DR+ AC (p-value=0.0249; Myeloid cell panel), CD4/CD8br (p-value=0.0355; TBNK panel), HLA DR on CD14+ CD16- monocyte (p-value=0.0397; mature stages of T cells panel) and CCR2 on CD62L+ myeloid DC (p-value=0.0483; cDC panel) exhibited an elevated risk of breast cancer development.